GH Research appoints Vanina Popova as chief development officer

GHRS•2026-11-13

GH Research appointed Vanina Popova as chief development officer. She will lead GH001 clinical development into pivotal programs for treatment-resistant depression and postpartum depression.

1. Development leadership

Popova joins from Johnson & Johnson after more than 20 years in neuroscience, including leading the pivotal TRANSFORM-2 trial for Spravato.

GH Research appoints Vanina Popova as chief development officer

1. Development leadership

Related News

AIM ImmunoTech Q3 2026 net loss narrows 6% to $3.1 million

Surrozen prices $60 million common stock offering at $31.67 a share

PAVmed Q3 2026 net loss more than doubles to $13.04 million

Owlet Q3 revenue falls 4.9% but beats expectations

Loop Industries falls short of Nasdaq minimum public float value requirement